Multiple-component solid phases containing at least one active pharmaceutical ingredient
OwnerMichael J. Zaworotko, Brian Moulton +1inventors
InventorsMichael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Life of this patent
Estimating the term…
Abstract
The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.
Claims36
A multiple-component phase composition comprising a solid phase that is sustained by intermolecular interactions between two or more independent molecular entities, wherein at least one of said two or more independent molecular entities is a pharmaceutical molecule.
The multiple-component phase composition of claim 15, wherein said complementary chemical functionalities include at least one chemical functionality selected from the group consisting of acids, amides, aliphatic nitrogen bases, unsaturated aromatic nitrogen bases, amines, alcohols, halogens, sulfones, nitro groups, S-heterocycles, N-heterocycles, O-heterocycles, ethers thioethers, thiols, esters, thioesters, thioketones, epoxides, acetonates, nitrils, oximes, and organohalides.
A multiple-component phase composition comprising a solid phase that is sustained by intermolecular interactions between aspirin and at least one independent molecular entity.
A multiple-component phase composition comprising a solid phase that is sustained by intermolecular interactions between acetaminophen and at least one independent molecular entity.
A multiple-component phase composition comprising a solid phase that is sustained by intermolecular interactions between a profen and at least one independent molecular entity.
A multiple-component phase composition comprising a solid phase that is sustained by intermolecular interactions between phenytoin and at least one independent molecular entity.
A multiple-component phase composition comprising a solid phase that is sustained by intermolecular interactions between carbamazepine and at least one independent molecular entity.
A method for identifying complementary chemical functionalities in order to form a desired supramolecular synthon, said method comprising:
- (a) evaluating the structure of an active pharmaceutical ingredient;
- (b) determining whether the active pharmaceutical ingredient contains chemical functionalities capable of forming supramolecular synthons with itself;
- (c) identifying from a plurality of chemical functionalities that are known to form a supramolecular synthon at least one functionality that will form a further supramolecular synthon to the supramolecular synthon formed by the active pharmaceutical ingredient, wherein the identified chemical functionality is not capable of disrupting non-covalent bonding within the supramolecular synthon formed by the supramolecular synthon formed by the active pharmaceutical ingredient, and wherein the selected chemical functionality is capable of forming a noncovalent bond to the supramolecular synthon formed by the active pharmaceutical ingredient;
- and
- (d) identifying co-crystal formers having chemical functionalities that are complementary with the active pharmaceutical ingredient.
A method for identifying complementary chemical functionalities in order to form a desired supramolecular synthon, said method comprising:
- (a) evaluating the structure of an active pharmaceutical ingredient;
- (b) determining whether the active pharmaceutical ingredient contains chemical functionalities capable of forming supramolecular synthons with itself;
- (c) identifying from a plurality of chemical functionalities that are known to form supramolecular synthons at least one functionality that will form a supramolecular synthon with the active pharmaceutical ingredient, wherein the identified chemical functionality is capable of disrupting non-covalent bonding within the supramolecular synthon formed by the active pharmaceutical ingredient, and wherein the selected chemical functionality is capable of forming a noncovalent bond to a complementary chemical functionality on the active pharmaceutical ingredient;
- and
- (d) identifying co-crystal formers having chemical functionalities that are complementary with the active pharmaceutical ingredient.
A method for identifying complementary chemical functionalities in order to form a desired supramolecular synthon, said method comprising:
- (a) evaluating the structure of an active pharmaceutical ingredient;
- (b) determining whether the active pharmaceutical ingredient contains chemical functionalities capable of forming supramolecular synthons with different molecules;
- (c) identifying from a plurality of chemical functionalities that are known to form supramolecular synthons at least one functionality that will form a supramolecular synthon with the active pharmaceutical ingredient, and wherein the selected chemical functionality is capable of forming a noncovalent bond to a complementary chemical functionality on the active pharmaceutical ingredient;
- and
- (d) identifying co-crystal formers having chemical functionalities that are complementary with the active pharmaceutical ingredient.
Dependencies are inferred from the claim text.